RxDoctor Payments Data

Nicole Harrell, MD

Dermatology · Baton Rouge, LANPI 1972763340

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 611 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,326, 2.1 times the $1,117 reported in 2019.

$9,864in general payments, 2019–2025

Across 611 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Sanofi$984
  • Novartis$863
  • Merz North America, Inc.$401
  • plus $3K from 30 others
$826,480in research payments, 2019–2025

Across 60 payments — averaging $13,775 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$694K
  • Eli Lilly$65K
  • AstraZeneca$35K
  • Dermira, Inc.$16K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Kiniksa Pharmaceuticals, Ltd.$7K
  • plus $2K from 1 others

What the payments were for

  • Food & beverage$9,67998%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,864 in reported general payments places this provider in the 75th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$209,144
Medicare patients
514
Services billed
13,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab75$291,719
Humira(Cf) PenAdalimumab21$278,128
Taltz AutoinjectorIxekizumab13$88,147
Dupixent SyringeDupilumab19$75,102
Clobetasol Propionate81$2,533
Tacrolimus24$2,511
Triamcinolone Acetonide206$1,954
Doxycycline Hyclate54$1,679
Ketoconazole95$1,669
Fluocinonide54$1,383
Metronidazole32$1,345
Fluorouracil20$1,238
Fluocinolone AcetonideFluocinolone/Shower Cap11$1,196
Finasteride62$826
Tretinoin16$721

Paid to pharmacies, not to this prescriber.

Other dermatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →